mRNA-1011.2 / Moderna - LARVOL DELTA

Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial. (PubMed, Lancet Infect Dis) - P1/2 | "These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage."

Journal • P1/2 data • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=700 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=700 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=700 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases